Retrophin Inc (RTRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Retrophin Inc (RTRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH374147D
  • |
  • Pages: 79
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Retrophin Inc (Retrophin) is a biopharmaceutical company that discovers, develops, acquires and commercializes drugs for the treatment of rare diseases. The company's products include thiola, chenodal and cholbam. It develops drugs for various catastrophic diseases. Retrophin's pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. The company operates in New York and Massachusetts, the US. Retrophin is headquartered in San Diego, California, the US.

Retrophin Inc (RTRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Retrophin Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Retrophin Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Retrophin Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Retrophin Acquires Liquid Formulation of Ursodeoxycholic Acid from Asklepion Pharma 12

Retrophin Acquires Cholic Acid Rights from Asklepion Pharma 13

Venture Financing 14

Perlstein Lab Raises USD2 Million in Seed Financing 14

Retrophin Raises USD 4 Million In Series A Financing 15

Partnerships 16

Retrophin Enters into Agreement with Censa Pharma 16

Retrophin Enters into Research Agreement with National Center for Advancing Translational Sciences and NGLY1 17

Retrophin Enters into Research Agreement with Grace Wilsey Foundation and Warren Family Research Center 18

Retrophin Enters into Agreement with Regents of the University of California 19

Licensing Agreements 20

Retrophin Amends Licensing Agreement with Mission Pharmacal for Thiola 20

Retrophin Enters into Licensing Agreement for Central Nervous System Disorders 21

Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 22

Retrophin Enters Into Licensing Agreement To Develop Product For Autism And Schizophrenia Treatment 23

Ligand Pharma Amends Licensing Agreement with Retrophin 24

Equity Offering 26

Retrophin Raises USD149.4 Million in Public Offering of Shares 26

Retrophin Raises USD40 Million in Public Offering of Shares 27

Retrophin Completes Private Placement Of Shares For USD 25 Million 29

Retrophin Announces Private Placement Of Common Stock For USD 10 Million 30

Debt Offering 31

Retrophin Raises USD276 Million in Public Offering of 2.5% Notes Due 2025 31

Retrophin Raises USD40 Million in Private Placement of Notes Due 2019 33

Asset Transactions 34

Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 34

Turing Pharma Acquires Vecamyl, Syntocinon and ketamine from Retrophin 35

Acquisition 37

Retrophin to Acquire Clinuvel Pharma 37

Retrophin Completes Acquisition Of Manchester Pharma For USD 62.5 Million 39

Retrophin Acquires Kyalin Biosciences for USD5 Million 40

Desert Gateway Completes Acquisition Of Retrophin In Reverse Takeover Transaction 41

Retrophin Inc-Key Competitors 42

Retrophin Inc-Key Employees 43

Retrophin Inc-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 46

Financial Announcements 46

Nov 01, 2018: Retrophin reports third quarter 2018 financial results 46

Jul 26, 2018: Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan 49

May 01, 2018: Retrophin Announces First Quarter 2018 Financial Results 52

Feb 27, 2018: Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results 54

Nov 07, 2017: Retrophin Reports Third Quarter 2017 Financial Results 56

Aug 09, 2017: Retrophin Reports Second Quarter 2017 Financial Results 58

May 04, 2017: Retrophin Reports First Quarter 2017 Financial Results 60

Mar 01, 2017: Retrophin Reports Fourth Quarter and Full Year 2016 Financial Results 61

Jan 09, 2017: Retrophin Provides Corporate Update and 2017 Preview 63

Corporate Communications 64

Jul 30, 2018: Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer 64

Aug 14, 2017: Retrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 65

Apr 12, 2017: Retrophin Appoints Ron Squarer to Board of Directors 66

Mar 23, 2017: John A. Orwin Joins Retrophin Board of Directors 67

Feb 13, 2017: Retrophin Appoints William Rote Senior Vice President, Research and Development 68

Legal and Regulatory 69

Aug 17, 2018: Shkreli Lawyer Gets 18-Month Sentence for Ponzi-Like Fraud 69

Aug 04, 2017: Former Hedge Fund Manager Convicted In Multi-Million Dollar Fraud Scheme 70

Clinical Trials 71

Jun 04, 2018: Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric Patients 71

Oct 05, 2017: Retrophin Announces Presentation of New Data from Physician-Initiated Treatment with Fosmetpantotenate at the Child Neurology Society's 26th Annual Meeting 72

Jul 25, 2017: Retrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN 74

May 25, 2017: Retrophin Announces Presentations On Late-Stage Clinical Development Program RE-024 at Upcoming Medical Congress 75

May 25, 2017: Retrophin Announces Presentations On Late-Stage Clinical Development Program Sparsentan at Upcoming Medical Congress 76

Mar 01, 2017: Retrophin Provides Sparsentan Regulatory Update 77

Other Significant Developments 78

Jan 08, 2018: Retrophin Provides Corporate Update and 2018 Outlook 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79

List of Figures

Retrophin Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Retrophin Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Retrophin Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Retrophin Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Retrophin Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Retrophin Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Retrophin Acquires Liquid Formulation of Ursodeoxycholic Acid from Asklepion Pharma 12

Retrophin Acquires Cholic Acid Rights from Asklepion Pharma 13

Perlstein Lab Raises USD2 Million in Seed Financing 14

Retrophin Raises USD 4 Million In Series A Financing 15

Retrophin Enters into Agreement with Censa Pharma 16

Retrophin Enters into Research Agreement with National Center for Advancing Translational Sciences and NGLY1 17

Retrophin Enters into Research Agreement with Grace Wilsey Foundation and Warren Family Research Center 18

Retrophin Enters into Agreement with Regents of the University of California 19

Retrophin Amends Licensing Agreement with Mission Pharmacal for Thiola 20

Retrophin Enters into Licensing Agreement for Central Nervous System Disorders 21

Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 22

Retrophin Enters Into Licensing Agreement To Develop Product For Autism And Schizophrenia Treatment 23

Ligand Pharma Amends Licensing Agreement with Retrophin 24

Retrophin Raises USD149.4 Million in Public Offering of Shares 26

Retrophin Raises USD40 Million in Public Offering of Shares 27

Retrophin Completes Private Placement Of Shares For USD 25 Million 29

Retrophin Announces Private Placement Of Common Stock For USD 10 Million 30

Retrophin Raises USD276 Million in Public Offering of 2.5% Notes Due 2025 31

Retrophin Raises USD40 Million in Private Placement of Notes Due 2019 33

Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 34

Turing Pharma Acquires Vecamyl, Syntocinon and ketamine from Retrophin 35

Retrophin to Acquire Clinuvel Pharma 37

Retrophin Completes Acquisition Of Manchester Pharma For USD 62.5 Million 39

Retrophin Acquires Kyalin Biosciences for USD5 Million 40

Desert Gateway Completes Acquisition Of Retrophin In Reverse Takeover Transaction 41

Retrophin Inc, Key Competitors 42

Retrophin Inc, Key Employees 43

Retrophin Inc, Other Locations 44

Retrophin Inc, Subsidiaries 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Retrophin Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17815
Site License
USD 500 INR 35630
Corporate User License
USD 750 INR 53445

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com